

Variant: *NM_000277.2(PAH):c.533A>G (p.Glu178Gly)*

Version: 1.1

[CA273110](#)

[92746 \(ClinVar\)](#)

Gene: PAH ([HGNC:5053](#))

Condition: phenylketonuria ([MONDO:0009861](#))

Inheritance Mode: Autosomal recessive inheritance

UUID: 9cbb36d6-2daf-4507-b947-3a692ec4d9e7

Approved on: 2025-04-18

Published on: 2025-04-18

HGVS expressions

NM_000277.2:c.533A>G

NM_000277.2(PAH):c.533A>G (p.Glu178Gly)

NC_000012.12:g.102855309T>C

CM000674.2:g.102855309T>C

NC_000012.11:g.103249087T>C

CM000674.1:g.103249087T>C

NC_000012.10:g.101773217T>C

NG_008690.1:g.67294A>G

NG_008690.2:g.108102A>G

ENST00000553106.6:c.533A>G

ENST00000307000.7:c.518A>G

ENST00000549111.5:n.629A>G

ENST00000551988.5:n.554A>G

ENST00000553106.5:c.533A>G

NM_000277.1:c.533A>G

NM_001354304.1:c.533A>G

NM_000277.3:c.533A>G

NM_001354304.2:c.533A>G

Pathogenic

Met criteria codes **5**

PP4_Moderate PS3_Supporting

PM2_Supporting PP3_Moderate

PM3_Strong

Evidence Links **0**

Expert Panel

Phenylketonuria VCEP

Criteria Specification Information

Criteria Specification: *ClinGen Phenylketonuria Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for PAH Version 2.0.0*

Criteria Specification Approval History











Criteria Specifications for this VCEP

Evidence submitted by expert panel

Phenylketonuria VCEP

The c.533A>G variant in PAH is a missense variant predicted to cause substitution of glutamine by glycine at amino acid 178 (p.Glu178Gly). At least 5 patients with this variant displayed serum Phe levels > 6.5–10 mg/dl which is highly specific for PAH deficiency; BH4 deficiency was excluded (PP4_moderate, PMID: 18299955, PMID:9634518). Of those individuals, 4 probands were compound heterozygous for the variant and a pathogenic variant and 1 proband was compound heterozygous with a likely pathogenic variant (phase unknown, 2.25 points). The population allele frequency in gnomAD v4.1 is 0.00003965 which is lower than the ClinGen PAH VCEP threshold (<0.0002) for PM2_Supporting, meeting this criterion (PM2_Supporting). The results from in silico predictors [REVEL=0.841], predict a damaging effect on PAH function (PP3_moderate). Enzyme activity assay showed 39% residual phenylalanine hydroxylase activity indicating that this variant impacts protein function (PMID:17935162)(PS3_supporting). In summary, this variant meets criteria to be classified as pathogenic for PAH deficiency in an autosomal recessive manner based on the ACMG/AMP criteria applied, as specified by the ClinGen PAH Expert Panel: PM2_supporting, PP3_moderate, PS3_supporting, PP4_Moderate, PM3_Strong (version 2.0, 11/16/2024).

Met criteria codes

PP4_Moderate			Detected in at least 5 patients with serum Phe levels > 6.5–10 mg/dl. BH4 deficiency excluded. PMID: 18299955, PMID: 9634518
PS3_Supporting			39% residual phenylalanine hydroxylase activity
PM2_Supporting			Total AF 0.00003965 in gnomAD v4.1
PP3_Moderate			REVEL=0.841
PM3_Strong			Detected with 3 pathogenic variants in 4 probands (0.5 points x 4 = 2.0 points) and 1 likely pathogenic variant (P281L) in 1 proband (0.25 points); phase unknown. 2.25 points

Curation History [↗](#)

Showing 1 to 2 of 2 rows

--

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.